The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2015 | Ongoing data from the phase 3 RESPONSE trial of ruxolitinib for polycythemia vera
Claire Harrison
• 12 Jun 2015
At the 20th Congress of the European Hematology Association (EHA), Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, provides an update on the phase 3 RESPONSE trial, which compared the JAK1/2 inhibitor, ruxolitinib, versus best available therapy in patients with polycythemia vera who were intolerant of or resistant to first-line therapy with hydroxyurea.
